中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (1): 67-70.doi: 10.12144/zgmfskin202601067

• 综述 • 上一篇    

JAK抑制剂在玫瑰痤疮中的应用

华凌云,夏汝山   

  1. 南京医科大学附属无锡市第二人民医院皮肤科,江苏无锡，214002
  • 出版日期:2026-01-15 发布日期:2026-01-16

Application of JAK inhibitors in rosacea

HUA Lingyun, XIA Rushan   

  1. Department of Dermatology, the Affiliated Wuxi No.2 People's Hospital of Nanjing Medical University, Wuxi 214002, China
  • Online:2026-01-15 Published:2026-01-16

PDF (PC)

12

摘要： 玫瑰痤疮是一种以面部红斑、毛细血管扩张、丘疹和脓疱为特征的慢性炎症性皮肤病，部分患者对传统治疗反应不佳或出现不良反应，近年来，Janus激酶（JAK）抑制剂作为一类新型靶向药物，因其在多种炎症性和自身免疫性疾病中的显著疗效而备受关注，其在玫瑰痤疮治疗中的潜力也逐渐被揭示。本文围绕JAK抑制剂，包括托法替布、阿布昔替尼、乌帕替尼、鲁索替尼，在玫瑰痤疮治疗中的机制、疗效及安全性进行综述。

关键词: 玫瑰痤疮, JAK抑制剂, 托法替布, 阿布昔替尼, 乌帕替尼, 鲁索替尼

Abstract: Rosacea is a chronic inflammatory skin disease characterized by facial erythema, telangiectasia, papules, and pustules. Some patients respond poorly to traditional treatments or experience adverse reactions. In recent years, Janus kinase (JAK) inhibitors, as a new targeted drugs, have attracted considerable attention due to their significant efficacy in various inflammatory and autoimmune diseases, and their potential in the treatment of rosacea has also been gradually revealed. We review the mechanisms, efficacy, and safety of JAK inhibitors, including tofacitinib, abrocitinib, upadacitinib, and ruxolitinib, in the treatment of rosacea.

Key words: rosacea, JAK kinase inhibitor, tofacitinib, abrocitinib, upadacitinib, ruxolitinib